PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.
about
Haloperidol dose for the acute phase of schizophreniaOlanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interactionModelling schizophrenia using human induced pluripotent stem cells.Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.Haloperidol dose for the acute phase of schizophrenia.Conventional versus novel antipsychotics: changing concepts and clinical implicationsAtypical neuroleptics in child and adolescent psychiatry.5-HT radioligands for human brain imaging with PET and SPECTEffect of smoking on the pharmacokinetics of inhaled loxapineIn vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.Serotonin: a review.Neuroreceptor imaging in psychiatric disorders.Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetLoxapine add-on for adolescents and adults with autism spectrum disorders and irritability.A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteersFirst- and second-generation antipsychotic medication and cognitive processing in schizophrenia.The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical ReviewCurrent status of positron emission tomography radiotracers for serotonin receptors in humans.Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.Revisiting loxapine: a systematic review.Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.The in vitro actions of loxapine on dopaminergic and serotonergic receptors. Time to consider atypical classification of this antipsychotic drug?
P2860
Q24200200-15111634-6E3D-4793-83E0-32325EDCA5A2Q24312756-0A0B3065-4A8A-47C5-A306-C8188D416EE8Q24633007-AC780613-545B-4640-BB06-C1F76CCDCAE6Q30501297-90B3DC5C-F570-4A8F-9125-77EC3CA83AFDQ30838771-9F15FE7D-200B-4A57-A176-7195126411D7Q33787546-73E29423-1DF7-4F04-9D66-9DFD5DDF483DQ34120084-B18B7DB3-30D8-4D03-A38F-B956A434DA4CQ34192729-C1ACF3ED-BAE3-466A-B3AE-75EE2D4CE0A2Q34445462-6654D4C2-45A7-4596-AD8F-EF63E5EF9537Q34631507-62551314-0F8F-44E8-8CD9-7B9CFDB77F49Q34652719-A84E9E53-14DD-4BF2-97FA-AAC83F15863CQ34777881-1B497DC0-0991-4D88-A183-0637F4962ECBQ35037212-40D669EB-3FE7-4A6F-AF34-9E6630A8FBBEQ35101377-4E004781-D684-442A-9FE2-59F51AAA98A8Q35200831-604CC3A6-EC0E-48B2-BBF0-A57BDC359079Q35641750-3F8C88FA-897E-4E57-9381-EC9D8939FA7AQ36177817-C4C20B59-8426-47C1-AF10-35DAEA6F8F14Q36228233-C4FBC014-2F5A-4AEC-A966-CB3BECA4C86BQ37690847-04EF9D95-D02E-47A4-9B2E-004C013752ADQ38166965-9EC26100-3240-4DBD-B42D-1D8285885525Q38170140-13261BC6-65C6-4CFD-BB76-61BE3AD3E338Q38413932-1AA444CD-50CF-4230-9E7B-86CBF5122008Q38881791-08B76D59-F2CA-417E-BAF3-E650A0490672Q41975639-C2F84C42-A375-46B2-B46C-05E795FADB57Q44381875-E0C28320-7763-464F-B3D1-513A16E5A72CQ47985236-0973F860-122C-4404-99D8-90FE0044A08D
P2860
PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
PET evidence that loxapine is ...... therapeutics of schizophrenia.
@en
PET evidence that loxapine is ...... therapeutics of schizophrenia.
@nl
type
label
PET evidence that loxapine is ...... therapeutics of schizophrenia.
@en
PET evidence that loxapine is ...... therapeutics of schizophrenia.
@nl
prefLabel
PET evidence that loxapine is ...... therapeutics of schizophrenia.
@en
PET evidence that loxapine is ...... therapeutics of schizophrenia.
@nl
P2093
P356
P1476
PET evidence that loxapine is ...... therapeutics of schizophrenia
@en
P2093
P304
P356
10.1176/AJP.154.11.1525
P407
P577
1997-11-01T00:00:00Z